Loading...
Please wait, while we are loading the content...
Similar Documents
Canadian Respiratory Journal 3 Medication Formoterol fumarate Salmeterol Salbutamol Fenoterol Terbutaline Fenoterol / ipratropium Salbutamol / ipratropium Ipratropium bromide Tiotropium bromide Salmeterol / fluticasone propionate Budesonide Theophylline Oxtriphylline Fluticasone propionate
| Content Provider | Semantic Scholar |
|---|---|
| Author | Tamdang-Tan Zhang, Shiyuan Tavares, Ruben V. Stutz, Melissa Ismaila, Afisi S. Vaillancourt, Julie Corriveau, Diane Stanford, Richard H. Lin, Xiwu Nadeau, Gilbert A. Simidchiev, Alexander Parsons, Daria Sampalis, John S. |
| Copyright Year | 2017 |
| Abstract | Background. Chronic obstructive pulmonary disease (COPD) prevalence in Canada has risen over time. COPD-related exacerbations contribute to the increased health care utilization (HCU) in this population. This study investigated the impact of exacerbations on COPD-related HCU.Methods. This retrospective observational cohort study used patient data from the Québec provincial health insurance databases. Eligible patients with a newHCU claimwith a diagnostic billing for COPDduring 2001–2010 were followed until March 31, 2011. Exacerbation rates and time to first exacerbation were assessed. Unadjusted analyses and multivariablemodels compared the rate ofHCUby exacerbation classification (any [moderate/severe],moderate, or severe).Results. The exacerbation event rate in patients with an exacerbation was 34.3 events/100 patient-years (22.7 for moderate exacerbations and 11.6 for severe exacerbations). Median time to first exacerbation of any classification was 37 months. In unadjusted analyses, COPD-related HCU significantly increased with exacerbation severity. In the multivariable, HCU rates were significantly higher after exacerbation versus before exacerbation (p < 0.01) for patients with an exacerbation or moderate exacerbations. For severe exacerbations, general practitioner, respiratory specialist, emergency room, and hospital visits were significantly higher after exacerbation versus before exacerbation (p < 0.001). Conclusions. Exacerbations were associated with increased HCU, which was more pronounced for patients with severe exacerbations. Interventions to reduce the risk of exacerbations in patients with COPD may reduce disease burden. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://downloads.hindawi.com/journals/crj/2017/8184915.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
